Class summary at a glance.

Every drug in the Anticholinergic class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 12tracked in Part D
CY24 Part D spend: $354.1Mcombined across class
Total Rx claims: 7.4M2.5M unique beneficiaries
Generic mfrs (active): 75across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Ipratropium

Brand: Atrovent · 3.6M Part D claims (CY24) · 1.6M beneficiaries · First FDA approval: 2001-09-27

10 generic mfrs 335 plans require PA

Low NADAC$0.099

→

Avg plan cost$1.07

Part D spend $244.7M 11× spread, current vs floor

Class share

69%

of class CY24 spend

View profile →

Scopolamine

Brand: Transderm Scop · 615K Part D claims (CY24) · 370K beneficiaries · First FDA approval: 2016-12-01

7 generic mfrs 96 plans require PA

Low NADAC$4.49

→

Avg plan cost$4.99

Part D spend $46.8M 1× spread, current vs floor

Class share

13%

of class CY24 spend

View profile →

Benztropine

2.9M Part D claims (CY24) · 455K beneficiaries · First FDA approval: 1992-01-23

12 generic mfrs 348 plans require PA Discontinued

Low NADAC$0.067

→

Avg plan cost$0.080

Part D spend $35.4M 1× spread, current vs floor

Class share

10%

of class CY24 spend

View profile →

Glycopyrrolate

Brand: Cuvposa · 373K Part D claims (CY24) · 98K beneficiaries · First FDA approval: 1990-09-30

35 generic mfrs 51 plans require PA

Low NADAC$0.103

→

Avg plan cost$0.643

Part D spend $15.4M 6× spread, current vs floor

Class share

of class CY24 spend

View profile →

Revefenacin

Brand: YUPELRI · 9K Part D claims (CY24) · 3K beneficiaries · First FDA approval: 2018-12-03

Brand-only (no generics) 36 plans require PA

Low NADAC$17.49

→

Avg plan cost$17.49

Part D spend $11.8M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Tropicamide

Brand: Mydriacyl · 1K Part D claims (CY24) · 1K beneficiaries · First FDA approval: 1959-04-01

7 generic mfrs

Low NADAC$0.498

→

Avg plan cost$0.897

Part D spend $12388 2× spread, current vs floor

Class share

of class CY24 spend

View profile →

Atropine

Brand: ATROPEN Auto-Injector · — Part D claims (CY24) · First FDA approval: 1971-01-01

Brand-only (no generics) 1 plans require PA

Low NADAC$4.33

→

Avg plan cost$9.00

Part D spend — 2× spread, current vs floor

Class share

of class CY24 spend

View profile →

Atropine Injection,

— Part D claims (CY24) · First FDA approval: 2018-07-09

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Atropine Sulfate Injection Usp,

— Part D claims (CY24) · First FDA approval: 2018-03-09

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Ipratropium and Albuterol

Brand: Combivent Respimat · — Part D claims (CY24) · First FDA approval: 2007-12-31

4 generic mfrs 328 plans require PA

Low NADAC$0.084

→

Avg plan cost$5.49

Part D spend — 65× spread, current vs floor

Class share

of class CY24 spend

View profile →

Scolopamine Transdermal System

Brand: Scopolamine Trandermal System · — Part D claims (CY24) · First FDA approval: 2017-06-13

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Scopolamine Transdermal System

— Part D claims (CY24) · First FDA approval: 2017-06-13

Brand-only (no generics) Discontinued

Low NADAC$4.49

→

Avg plan cost$4.49

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.